Clinical Trials Browser

Triple Negative Breast Neoplasms × tislelizumab × Clear all

Carcinoma, Stomach Neoplasms, Leukemia, Myeloid, Acute, Triple Negative Breast Neoplasms

NCT06538896 2024-11-26

Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study

Phase 2 Recruiting

20 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06448169 2024-06-07

Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancer

Not yet recruiting

200 enrolled

Breast

Hypersensitivity, Triple Negative Breast Neoplasms

NCT04914390 2024-01-22

NeoATCT

Phase 2 Unknown

32 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04734262 2023-11-18

SPARK

Phase 2 Unknown

98 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05809895 2023-07-24

AdvanTIG-211

Phase 2 Withdrawn

Breast

Triple Negative Breast Neoplasms

NCT05746728 2023-04-06

Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

Phase 1/2 Unknown

45 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04501523 2023-02-21

Apollo

Phase 2 Recruiting

460 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04913571 2021-06-04

TEMPLATE

Phase 2 Unknown

265 enrolled

Breast

Triple Negative Breast Neoplasms

Clinical Trials

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study

Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancer

NeoATCT

SPARK

AdvanTIG-211

Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

Apollo

TEMPLATE